Brain Derived Neurotrophic Factor (Abrineurin or BDNF) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Brain Derived Neurotrophic Factor (Abrineurin or BDNF) – Pipeline Review, H2 2016’, provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics.

The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Brain Derived Neurotrophic Factor (Abrineurin or BDNF)

The report reviews Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics and enlists all their major and minor projects

The report assesses Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Brain Derived Neurotrophic Factor (Abrineurin or BDNF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Brain Derived Neurotrophic Factor (Abrineurin or BDNF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AudioCure Pharma GmbH

ReCyte Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) Overview 6

Therapeutics Development 7

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Stage of Development 7

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Therapy Area 8

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Indication 9

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Companies 12

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Universities/Institutes 14

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Companies Involved in Therapeutics Development 23

AudioCure Pharma GmbH 23

ReCyte Therapeutics Inc 24

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Drug Profiles 25

AC-002 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

CNB-001 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Gene Therapy to Activate BDNF for Parkinson’s Disease - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

smilagenin - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Stem Cell Therapy for Ischemic Stroke - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Dormant Projects 33

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Featured News & Press Releases 34

Apr 10, 2015: Evidence of the efficacy of AC002 34

Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 34

Feb 18, 2013: Phytopharm Announces Results From Parkinson’s Disease Clinical Trial Of Cogane 34

Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 36

Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease 36

Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 37

Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 38

Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 39

Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 40

Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 40

Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 41

Apr 20, 2009: Phytopharm Announces the Commencement of Clinical Study of Cogane in Patients with Parkinson’s disease 41

Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 42

Jun 05, 2007: Phytopharm plc Presents Cogane Data At ‘11th International Congress Of Parkinson’s Disease And Movement Disorders’ 43

Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by AudioCure Pharma GmbH, H2 2016 23

Pipeline by ReCyte Therapeutics Inc, H2 2016 24

Dormant Projects, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared